Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;65(1):177-188.
doi: 10.1007/s12088-024-01404-5. Epub 2024 Oct 7.

Nanotechnology-Based Modern Biosensors for the Detection of SARS-CoV-2 Virus

Sandhya Devi  1 , Neha Yadav  1   2 , Rakesh Yadav  1
Affiliations
Review

Nanotechnology-Based Modern Biosensors for the Detection of SARS-CoV-2 Virus

Sandhya Devi et al. Indian J Microbiol. 2025 Mar.

Abstract

The emergence of the COVID-19 pandemic has pointed out the urgent need for rapid and accurate diagnostic tools to detect the SARS-CoV-2 virus. Nanotechnology-based biosensors have emerged as a promising solution due to their high sensitivity, specificity, and speed in detecting biological molecules. This article focuses on the advancements in using nanotechnology for the development of modern biosensors tailored for the detection of the SARS-CoV-2 virus. Various nanomaterials, such as quantum dots, metallic nanoparticles, and nanowires, have been harnessed to enhance the performance of biosensors, offering improved detection limits and specificity. Besides this, innovative detection platforms, such as field-effect transistors, surface plasmon resonance, and electrochemical sensors, have revolutionized the landscape of SARS-CoV-2 diagnostics. These nanotechnology-based biosensors demonstrate the potential for point-of-care testing, enabling rapid and on-site detection with minimal sample preparation. The scalability, cost-effectiveness, and portability of these biosensors make them suitable for mass screening efforts in various healthcare settings, including hospitals, clinics, and community centers. The development of reliable biosensors for SARS-CoV-2 detection aligns with global efforts to curb the spread of the virus through early identification and containment strategies.

Keywords: Biosensor; COVID-19; Detection; Nanomaterials; Nanotechnology; SARS-CoV-2.

PubMed Disclaimer

Similar articles

  • Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, Taylor M, Cunningham J, Davenport C, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Van den Bruel A, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Dinnes J, et al. Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
  • Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Domen J, Tans A, Janssens S, Wickramasinghe D, Lannoy V, Horn SRA, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Struyf T, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
  • Measures implemented in the school setting to contain the COVID-19 pandemic.
    Krishnaratne S, Littlecott H, Sell K, Burns J, Rabe JE, Stratil JM, Litwin T, Kreutz C, Coenen M, Geffert K, Boger AH, Movsisyan A, Kratzer S, Klinger C, Wabnitz K, Strahwald B, Verboom B, Rehfuess E, Biallas RL, Jung-Sievers C, Voss S, Pfadenhauer LM. Krishnaratne S, et al. Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 May 2;5:CD015029. doi: 10.1002/14651858.CD015029.pub2. PMID: 35037252 Free PMC article. Updated.
  • Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, Hettiarachchi D, Mathangasinghe Y, Weeratunga P, Wickramasinghe D, Bergman H, Buckley BS, Probyn K, Sguassero Y, Davenport C, Cunningham J, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Struyf T, Van den Bruel A, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Fox T, et al. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
  • Nanomaterial-Based Biosensors for the Detection of COVID-19.
    Tewari M, Rana P, Pande V. Tewari M, et al. Indian J Microbiol. 2025 Mar;65(1):120-136. doi: 10.1007/s12088-024-01336-0. Epub 2024 Jun 23. Indian J Microbiol. 2025. PMID: 40371045
See all similar articles

References

    1. Taha BA, Mashhadany YA, Jubouri QA, Rashid AZBA, Luo Y, Chen Z, Rustagi S, Chaudhary V, Arsad N (2023) Next-generation nanophotonic-enabled biosensors for intelligent diagnosis of SARS-CoV-2 variants. Sci Total Environ 880:163333 - PMC - PubMed
    1. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, Megawati D, Hayati Z, Wagner AL, Mudatsir M (2020) Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 13:667–673. 10.1016/j.jiph.2020.03.019 - PMC - PubMed
    1. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, Chen H, Mubareka S, Gubbay JB, Chan WCW (2020) Diagnosing COVID-19: the disease and tools for detection. ACS Nano 14:3822–3835. 10.1021/acsnano.0c02624 - PubMed
    1. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A (2021) COVID-19 Genomics UK (COG-UK) Consortium; Peacock SJ, Robertson DLl: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424. 10.1038/s41579-021-00573-0 - PMC - PubMed
    1. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J, Gallagher E, Charlett A, De Angelis D, Presanis AM, Dabrera G (2022) COVID-19 Genomics UK (COG-UK) consortium. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 22:35–42. 10.1016/S1473-3099(21)00475-8. - PMC - PubMed

LinkOut - more resources